[1] Jorritsma R, Jorritsma H, Schukken Y H, Wentink G H. Relationships between fatty liver and fertility and some periparturient diseases in commercial Dutch dairy herds. Theriogenology, 2000, 54 (7): 1065-1074.
[2] Grummer R R. Etiology of lipid-related metabolic disorders in periparturient dairy cows. Journal of Dairy Science, 1993, 76(12): 3882-3896.
[3] Bobe G, Young J W, Beitz D C. Invited review: pathology, etiology, prevention, and treatment of fatty liver in dairy cows. Journal of Dairy Science, 2004, 87(10):3105-3124.
[4] Katoh N. Relevance of apolipoproteins in the development of fatty liver and fatty liver-related peripartum diseases in dairy cows. Journal of Veterinary Medical Science,2002, 64(4):293-307.
[5] Cebra C K, Garry F B, Getzy D M, Fettman M J. Hepatic lipidosis in anorectic, lactating holstein cattle: a retrospective study of serum biochemical abnormalities. Journal of Veterinary Medical Science, 1997, 11(4):231-237.
[6] 田萍, 郝贵增, 徐闯, 苏蔚. 奶牛局限性脂肪肝的超声诊断. 安徽农业科学, 2007, 35(14):4199-4200.
Tian P, Hao G Z, Xu C, Su W. Limitations ultrasound diagnosis of fatty liver cows. Journal of Anhui Agricultural Sciences, 2007, 35(14):4199-4200. (in Chinese)
[7] Zou M, Arentson E J, Teegarden D, Koser SL, Onyskow L, Donkin S S. Fructose consumption during pregnancy and lactation induces fatty liver and glucose intolerance in rats. Nutrition Research (New York, NY), 2012, 32(8):588-598.
[8] Farid A S, Honkawa K, Fath E M, Nonaka N, Horii Y. Serum paraoxonase-1 as biomarker for improved diagnosis of fatty liver in dairy cows. BMC Veterinary Research, 2013(9): 73.
[9] Weisel J W. Fibrinogen and fibrin.Advances in Protein Chemistry, 2005, 70:247-299.
[10] Scheraga H A. The thrombin-fibrinogen interaction. Biophysical Chemistry, 2004, 112(2-3):117-130.
[11] 彭运生, 董临江. 脂肪肝患者血浆纤维蛋白原与纤维蛋白单体聚合功能的测定及临床意义. 中西医结合肝病杂志, 2001, 11(4): 206-207.
Peng Y S, Dong L J. Determination of function of plasma fibrinogen and fibrin monomer polymerization and Clinical Significance. Chinese Journal of Integrated Traditional and Westem Medicine on Liver Disease, 2001, 11 (4): 206-207. (in Chinese)
[12] Johnson M, Alper A, Rosen C, Craig F S, John M. C1 Inhibitor evidence for decreased Hepatic synthesis in Hereditary Angioneurotic. Edema Science, 1971, 173 (3996): 553-554. PMID: 4935379.
[13] Sim R B, Reboul A. Preparation and properties of human Cl inhibitor. Methods in Enzymology, 1981, 80: 43-54. PMID: 6281621.
[14] Li Z, Soloski M J, Diehl A M. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology, 2005, 42: 880-885.
[15] Pritchard M T, McMullen M R, Stavitsky A B, Cohen J I, Lin F, Medof M E, Nagy L E. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.Gastroenterology, 2007, 132: 1117-1126.
[16] Solís Herruzo J A,García R I,Pérez C M,Muñoz Yagüe M T. N on-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Revista Espanola de Enfermedades Digestivas, 2006, 98: 844-874.
[17] Bykov I, Junnikkala S, Pekna M, Lindros K O, Meri S. Complement C3 contributes to ethanol-induced liver steatosis in mice. Annals of Medicine, 2006, 38: 280-286.
[18] Zetterberg H, Blennow K, Hanse E. Amyloidβand APP as biomarkers for Alzheimer’s disease. Experimental Gerontology, 2010, 45(1): 23-29. PMID: 19698775.
[19] Hampel H, Shen Y, Walsh D M, Aisen P, Shaw L M, Zetterberg H, Trojanowski J Q, Blennow K. Biological markers of amyloid β-related mechanisms in Alzheimer's disease. Experimental Neurology, 2010, 223(2): 334-346. PMID: 19815015
[20] Mattson, M P. Pathways towards and away from Alzheimer’s disease. Nature, 2004, 430: 631-639. PMID: 15295589.
[21] Walsh D M, Selkoe D J. A beta oligomers—a decade of discovery. Journal of Neurochemistry, 2007, 101: 1172-1184. PMID: 17286590
[22] 周 玢,洪 震. 阿尔茨海默病患者中胰岛素与β样淀粉蛋白的关系. 中国神经精神疾病杂志, 2003, 29(1): 24-26.
Zhou F, Hong Z. The relationship of insulin and β amyloid protein in Alzheimer's disease. Chinese Journal of Nervous and Mental Disease, 2003, 29 (1): 24-26. (in Chinese)
[23] 刘 军. 脂肪肝与糖尿病的研究进展. 医学综述, 2002, 8(11): 657-659.
Liu J. Progress of fatty liver and diabetes. Medical Recapitulate, 2002, 8 (11): 657-659. (in Chinese)
[24] Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, Uesato M, Inada S, Kamatani N. A novel single- nucleotide Polymorphism at the 5’-flallking region of SAA1 associated with risk of type AA amyloidosis Secondary to rheumatoid arthritis.Arthritis & Rheumatism, 2001, 44(6):1266-1272.
[25] Cabana V G, Feng N, Reardon C A, Lukens J, Webb N R, de Beer F C, Getz G S. Influence of apoA-Ⅰ and apoE on the Formation of serum amyloid A-containing lipoproteins in vivo and in vitro. Journal of Lipid Research, 2004, 45(2):317-325.
[26] Hosoai H, Webb N R, Glick J M, Tietge U J, Purdom M S, de Beer F C, Rader D J. Expression of serum amyloid A Protein in The absence of the acute phase response does not reduce HDL cholesterolor apoA-Ⅰ levels in human apoA-Ⅰ transgenic mice. Journal of Lipid Research, 1999, 40 (4):648-653.
[27] Hokanson J E, Kinney G L, Cheng S, Erlich H A, Kretowski A, Rewers M. Susceptibility to type1diabetes is associated with ApoCIII gene haplotypes. Diabetes, 2006, 55(3): 834-838. PMID: 16505251.
[28] Duivenvoorden I, Teusink B, Rensen P C, Romijn J A, Havekes L M, Voshol P J. Apolipo protein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes, 2005, 54 (3): 664-671.
[29] Beck F K, Rosenthal T C. Prelbumin: a Marker for Nutritional Evaluation. American Family Physician, 2002, 65(8): 1575-1578.
[30] 白晓苏, 龚莉琳, 张素华, 李 蓉, 任 伟, 张闻宇, 程庆丰. 肥胖患者转甲状腺素蛋白水平的研究. 第三军医大学学报, 2007, 29(10): 970-972.
Bai X S, Gong L L, Zhang S H, Li R, Ren W, Zhang W Y, Cheng Q F. Research of transferred transthyretin levels in obese patients, Journal of Third Military Medical University, 2007, 29(10):970-972. (in Chinese)
[31] 彭晨. 转甲状腺素蛋白在肿瘤研究中的进展[D].蚌埠: 蚌埠医学院, 2014.
Peng C. Progress of transthyretin in cancer research[D]. Bangbu: Bengbu Medical College,2014. (in Chinese)
[32] Nicolas G,Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S.Lack of hepcid in gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) Knockout mice. Proceedings of the National Academy of Sciences USA, 2001,98(15): 8780-8785.
[33] Kulaksiz H, Gehrke S G, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochrom atosis, chronic renal insuficiency, and renal anemia. Gut, 2004; 53(5): 735-743.
[34] Kulaksiz H, Theilig F, Bachmann S, Gehrke S G, Rost D, Janetzko A, Cetin Y, Stremmel W. The iron-regulatory peptide hormone hepcid in: Expression and cellular localization in the mammaliank idney. Journal of Endocrinology,2005; 184(2): 361-370.
[35] Nicolas G, Chauvet C, Viatte L, Danan J L, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. Journal of Clinical Investigation, 2002, 110(7): 1037-1044.
[36] Marastoni S, Ligresti G, Lorenzon E, Colombatti A, Mongiat M. Extraeellular matrix:a matter of life and death. Connective Tissue Research,2008, 49:203-206.
[37] Morozevieh G E, Kozlova N, Preobrazhen skaya M E, Ushakova N A, Eltsov I A, Shtil A A, Berman A E. The role of beta1 integrin subfamily in anehorage-dePendent apoptosis of breast careinoma cells Differing in multidrug resistance. Biochemistry (Mosc). 2006, 71: 489-495.
[38] Mareoni A, Atzei P, Panza C, Fila C, Tiberio R, Truzzi F, Wachter T, Leverkus M, Pincelli C. FLICE/caspase-8 activation Triggers anoikis induced by betal-integrin blockade in human keratinoeytes. Journal of Cell Science, 2004:117:5815-5823.
[39] Zhang Q, Wrana J L, Sodek J. Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a 'silent' second promoter. European Journal of Biochemistry, 1992, 207(2): 649-659.
[40] Lund S A, Giachelli C M, Scatena M. The role of osteopontin in inflammatory processes. Cell Communication and Signaling, 2009, 3(3-4): 311-322.
[41] Levi A, Eldridge J D, Paterson B M. Molecular cloning of a gene sequence regulated by nerve growth factor. Science, 1985, 229: 393-395.
[42] Snyder S E, Peng B, Pintar J E, Salton S R. Expression of VGF mRNA in developing neuroendocrine and endocrine tissues. Endocrinology, 2003, 179:227-235.
[43] Hahm S, Fekete C, Mizuno T M, Windsor J, Yan H, Boozer C N, Lee C, Elmquist J K, Lechan R M, Mobbs C V, Salton S R. VGF is required for obesity induced by diet, gold thioglucose treatment and agouti, and is ferentially regulated in POMC- and NPY-containing arcuate neurons in response to fasting.Journal of Neuro Science, 2002, 22:6929-6938.
[44] Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser D F, Sanchez J C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics, 2003, 3(8): 1486-1494.
[45] Lafarge J C, Naour N, Clément K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie, 2010, 92(11): 1580-1586.
[46] 陈 颖,葛毅强,张利明,李文彬. 哺乳动物防御素的研究进展及其应用前景. 生物化学与生物物理进展, 2001, 28(1): 17-21.
Chen Y, Ge Y Q, Zhang L M, Li W B. Research progress and application prospect of mammalian defensins. Progress in Biochemistry and Biophysics, 2001, 28 (1): 17-21. (in Chinese)
[47] 陈 意,陶人川,林雪芳,刘贞敏. 人中性粒细胞防御素1~3的日节律性分泌. 国际口腔医学杂志, 2013(4): 429-431.
Chen Y, Tao R C, Lin X F, Liu Z M. Daily rhythm secretion of human neutrophil defensin 1-3. International Journal of Stomatology, 2013(4): 429-431. (in Chinese) |